Skip to content

American Battery Technology Company ABAT Reductions To Research And Development Costs

Reductions To Research And Development Costs at other companies

ADTRAN Holdings, Inc. logo
ADTRAN Holdings, Inc.ADTN
$2.95M+28.3%
Adient logo
AdientADNT
$72M+2.9%
Replimune Group logo
Replimune GroupREPL
$341K-9.3%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$319K-41.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$18.66M-32.4%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.49M+25.5%

Other financials

Income statement

See full
Revenue$7.8M+697%
Gross profit$737.7K+127%
Operating income-$34.4M-223%
Net income-$33.8M-194%
EPS (diluted)-$0.26-85.7%

Balance sheet

See full
Cash & equivalents$37.7M+1,223%
Total debt$220.6K-96.9%
Total equity$112.8M+71.9%
Total assets$119.4M+56.2%

Cash flow

See full
Operating cash flow-$2.7M+73.7%
CapEx$6.7M+1,268%
Free cash flow-$9.4M+12.8%

Valuation

See full
Market cap$368.32M+213%
Enterprise value$330.85M+172%
P/S22.6×-50.8×

Profitability

See full
Gross margin-42.7%-20.5pp
Operating margin-381.9%-180pp
Net margin-390.5%-185pp
FCF margin-211.1%-99.1pp

Returns & leverage

See full
Return on equity-71.3%-11.1pp
Debt / equity-0.1×
Current ratio8.1×+5.9×

Where this comes from

Reported directly by American Battery Technology Company in its filing.

Tagged under the XBRL concept ABAT:ReductionsToResearchAndDevelopmentCosts.

The official record: American Battery Technology Company’s 10-K, filed September 18, 2025, on SEC EDGAR. View the filing →

Ask your AI about American Battery Technology Company's reductions to research and development costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is American Battery Technology Company's reductions to research and development costs?
American Battery Technology Company (ABAT) reported reductions to research and development costs of $5.09M in Q2 2025.
What does reductions to research and development costs mean?
Credits, reimbursements, or cost offsets that reduce the gross expenditure on research and development activities. This metric helps investors understand the net cost of innovation after accounting for external subsidies or partner contributions.